Cargando…
The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer
Prostate cancer is the most common cancer in men and the second leading cause of cancer-related deaths. The most used biomarker to detect prostate cancer is Prostate Specific Antigen (PSA), whose levels are measured in serum. However, it has been recently established that molecular markers of cancer...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945524/ https://www.ncbi.nlm.nih.gov/pubmed/29755696 http://dx.doi.org/10.18632/oncotarget.25038 |
_version_ | 1783322006522953728 |
---|---|
author | Arriaga-Canon, Cristian De La Rosa-Velázquez, Inti Alberto González-Barrios, Rodrigo Montiel-Manríquez, Rogelio Oliva-Rico, Diego Jiménez-Trejo, Francisco Cortés-González, Carlo Herrera, Luis A. |
author_facet | Arriaga-Canon, Cristian De La Rosa-Velázquez, Inti Alberto González-Barrios, Rodrigo Montiel-Manríquez, Rogelio Oliva-Rico, Diego Jiménez-Trejo, Francisco Cortés-González, Carlo Herrera, Luis A. |
author_sort | Arriaga-Canon, Cristian |
collection | PubMed |
description | Prostate cancer is the most common cancer in men and the second leading cause of cancer-related deaths. The most used biomarker to detect prostate cancer is Prostate Specific Antigen (PSA), whose levels are measured in serum. However, it has been recently established that molecular markers of cancer should not be based solely on genes and proteins but should also reflect other genomic traits; long non-coding RNAs (lncRNAs) serve this purpose. lncRNAs are transcripts of >200 bases that do not encode proteins and that have been shown to display abnormal expression profiles in different types of cancer. Experimental studies have highlighted lncRNAs as potential biomarkers for prognoses and treatments in patients with different types of cancer, including prostate cancer, where the PCA3 lncRNA is currently used as a diagnostic tool and management strategy. With the development of genomic technologies, particularly next-generation sequencing (NGS), several other lncRNAs have been linked to prostate cancer and are currently under validation for their medical use. In this review, we will discuss different strategies for the discovery of novel lncRNAs that can be evaluated as prognostic biomarkers, the clinical impact of these lncRNAs and how lncRNAs can be used as potential therapeutic targets. |
format | Online Article Text |
id | pubmed-5945524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59455242018-05-13 The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer Arriaga-Canon, Cristian De La Rosa-Velázquez, Inti Alberto González-Barrios, Rodrigo Montiel-Manríquez, Rogelio Oliva-Rico, Diego Jiménez-Trejo, Francisco Cortés-González, Carlo Herrera, Luis A. Oncotarget Review Prostate cancer is the most common cancer in men and the second leading cause of cancer-related deaths. The most used biomarker to detect prostate cancer is Prostate Specific Antigen (PSA), whose levels are measured in serum. However, it has been recently established that molecular markers of cancer should not be based solely on genes and proteins but should also reflect other genomic traits; long non-coding RNAs (lncRNAs) serve this purpose. lncRNAs are transcripts of >200 bases that do not encode proteins and that have been shown to display abnormal expression profiles in different types of cancer. Experimental studies have highlighted lncRNAs as potential biomarkers for prognoses and treatments in patients with different types of cancer, including prostate cancer, where the PCA3 lncRNA is currently used as a diagnostic tool and management strategy. With the development of genomic technologies, particularly next-generation sequencing (NGS), several other lncRNAs have been linked to prostate cancer and are currently under validation for their medical use. In this review, we will discuss different strategies for the discovery of novel lncRNAs that can be evaluated as prognostic biomarkers, the clinical impact of these lncRNAs and how lncRNAs can be used as potential therapeutic targets. Impact Journals LLC 2018-04-17 /pmc/articles/PMC5945524/ /pubmed/29755696 http://dx.doi.org/10.18632/oncotarget.25038 Text en Copyright: © 2018 Arriaga-Canon et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Arriaga-Canon, Cristian De La Rosa-Velázquez, Inti Alberto González-Barrios, Rodrigo Montiel-Manríquez, Rogelio Oliva-Rico, Diego Jiménez-Trejo, Francisco Cortés-González, Carlo Herrera, Luis A. The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title | The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title_full | The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title_fullStr | The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title_full_unstemmed | The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title_short | The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer |
title_sort | use of long non-coding rnas as prognostic biomarkers and therapeutic targets in prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945524/ https://www.ncbi.nlm.nih.gov/pubmed/29755696 http://dx.doi.org/10.18632/oncotarget.25038 |
work_keys_str_mv | AT arriagacanoncristian theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT delarosavelazquezintialberto theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT gonzalezbarriosrodrigo theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT montielmanriquezrogelio theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT olivaricodiego theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT jimeneztrejofrancisco theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT cortesgonzalezcarlo theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT herreraluisa theuseoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT arriagacanoncristian useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT delarosavelazquezintialberto useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT gonzalezbarriosrodrigo useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT montielmanriquezrogelio useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT olivaricodiego useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT jimeneztrejofrancisco useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT cortesgonzalezcarlo useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer AT herreraluisa useoflongnoncodingrnasasprognosticbiomarkersandtherapeutictargetsinprostatecancer |